Will GSK escape from misfortune in its vaccine business?

GSK, which used be called the strong but has had difficulties in vaccine, is planning to announce its ambitious work after a long time.

The GSK’s ambitious work is the shingles vaccine ‘HZ/su.’ It has been recently shown that the group of the GSK’s shingles vaccination has 97.2% lower in the shingles incidence than the placebo group in the placebo controlled Phase 3 clinical trial, ‘ZOE-50,’ t...